Table 2 of
Daull, Mol Vis 2018; 24:459-470. Table 2 of
Daull, Mol Vis 2018; 24:459-470.
Table 2. Summary of the experimental conditions used for the secretion inhibition in vitro assays.
| Cell type | Stimulation (dose) | Positive ctls (dose) | Incubation time | Markers | Marker quantification method |
|---|---|---|---|---|---|
| PBMC | LPS | DXM | 24h | IL-6 | FC: BDTM CBA kit (558,276) |
| IL-8 | FC: BDTM CBA kit (558,277) | ||||
| IL-12 | FC: BDTM CBA kit (560,154) | ||||
| TNFα | FC: BDTM CBA kit (558,273) | ||||
| PBMC | Anti CD3 & anti CD28 | CsA | 24h | IL-2 | FC: BDTM CBA kit (558,270) |
| IL-10 | FC: BDTM CBA kit (558,274) | ||||
| INFγ | FC: BDTM CBA kit (558,269) | ||||
| TNFα | FC: BDTM CBA kit (558,273) | ||||
| T CD4+ | Anti CD3 & anti CD28 | CsA | 24h | INFγ | ELISA: DIACLONE (851,560,005) |
| TNFα | ELISA: DIACLONE (851,570,015) | ||||
| 72h | IL-17 | ELISA: R&D system (DY208) | |||
| HCE-2 | LPS | IKK inhX | 24h | IL-6 | ELISA: R&D system (DY206) |
| IL-8 | ELISA: R&D system (DY208) |